Novo Nordisk Pharma is a global pharmaceutical company founded in 1923 (in Poland since 1991) with its headquarters in Denmark. Its activities are focused on the treatment of diabetes and other severe chronic diseases, such as obesity, and rare hematological and endocrinological disorders. Novo Nordisk employs approximately 44,000 people in 80 countries worldwide, and its products are available in 170 countries. Novo Nordisk produces 50% of the world’s insulin, with more than 34 million diabetes patients using the company's products.